BioCentury | May 30, 2020
Translation in Brief

Empirica’s glioblastoma CAR T therapy in mice; plus tumor microbiomes by tumor type, Senhwa and more

...New Source of Translational Opportunities” ). New target for Senhwa synthetic lethal compound CX-5461 from Senhwa Biosciences Inc....
...pathway has been a major focus of research exploring synthetic lethality interactions beyond PARP-BRCA . Senhwa...
...Tuzman, Associate Editor CX-5461 American Society of Clinical Oncology ASCO Weizmann Institute of Science McMaster University Empirica Therapeutics Medical University of South Carolina Senhwa Biosciences Inc. Breast...
BioCentury | Feb 5, 2019
Distillery Therapeutics

Cancer

...6 μM, respectively). Next steps could include testing the compound in mouse models of RCC. Senhwa Biosciences Inc....
BioCentury | Mar 16, 2018
Finance

Hong Kong’s new chapter

...big hit. TPEx has made a comeback, with seven IPOs in 2016-17 that culminated with Senhwa Biosciences Inc.’s...
...Inc., Zhubei, Taiwan Medigen Biotechnology Corp. (TPEx:3176), Taipei, Taiwan OBI Pharma Inc. (TPEx:4174), Taipei, Taiwan Senhwa Biosciences Inc....
BioCentury | Mar 2, 2018
Clinical News

Senhwa reports Phase I data for CX-5461 in hematologic malignancies

...in December 2017. The trial was conducted in collaboration with the Peter MacCallum Cancer Centre. Senhwa...
...CX-5461 is an oral RNA polymerase I (Pol I) inhibitor and G-quadruplex (G4) DNA stabilizer. Senhwa Biosciences Inc....
...and antitumor activity Status: Phase I data Milestone: Start Phase II (2018) Mary Romeo CX-5461 American Society of Hematology ASH Senhwa Biosciences Inc. RNA...
BioCentury | Dec 22, 2017
Financial News

JHL delisting from TPEx

...next year. JHL Biotech Inc. (TPEx-E:6540), Zhubei, Taiwan Jaime De Leon JHL1101 Genentech Inc. JHL Biotech Inc. Medigen Biotechnology Corp. PharmaEngine Inc. Roche Senhwa Biosciences Inc. TaiGen...
BioCentury | Dec 21, 2017
Financial News

JHL delisting from TPEx

...multiple trials of the candidates next year. Jaime De Leon dornase alfa Herceptin JHL1101 Pulmozyme Rituxan rituximab Genentech Inc. JHL Biotech Inc. Medigen Biotechnology Corp. PharmaEngine Inc. Roche Senhwa Biosciences Inc. TaiGen...
BioCentury | Dec 9, 2017
Product Development

Multimodal meeting

...is developing BNZ-1 to treat large granular lymphocyte leukemia and cutaneous T cell lymphoma (CTCL). Senhwa Biosciences Inc....
...response (PR) at 24 weeks in 14 patients 3256 RNA polymerase I (Pol I) CX-5461 Senhwa Biosciences Inc....
...to treat leukemias Safety, HA-1 specific CD8+ T cell response in 9 healthy volunteers 1908 Senhwa Biosciences Inc....
BioCentury | Aug 17, 2017
Translation in Brief

Stopping the invasion

...in the brain slice model, and in an orthotopic xenograft mouse model (see Distillery ). Senhwa Biosciences Inc....
...a druggable pathway controlling glioblastoma invasiveness." Cell Reports (2017) Winnie Pong, Staff Writer CX-4945 Curtana Pharmaceuticals Inc. Netherlands Cancer Institute Senhwa Biosciences Inc. Casein...
BioCentury | Aug 16, 2017
Distillery Therapeutics

Cancer

...therapies in animal models of GBM (see "Stopping the Invasion." BioCentury Innovations (Aug. 17, 2017)). Senhwa Biosciences Inc....
BioCentury | Jul 7, 2017
Finance

Generalists needed

...NASDAQ:URGN) 5/3/17 $58.2 $155.6 $216.2 39% Zymeworks Inc. (NYSE:ZYME; TSX:ZYME) 4/27/17 $63.6 $319.7 $211.4 -34% Senhwa Biosciences Inc....
Items per page:
1 - 10 of 20
BioCentury | May 30, 2020
Translation in Brief

Empirica’s glioblastoma CAR T therapy in mice; plus tumor microbiomes by tumor type, Senhwa and more

...New Source of Translational Opportunities” ). New target for Senhwa synthetic lethal compound CX-5461 from Senhwa Biosciences Inc....
...pathway has been a major focus of research exploring synthetic lethality interactions beyond PARP-BRCA . Senhwa...
...Tuzman, Associate Editor CX-5461 American Society of Clinical Oncology ASCO Weizmann Institute of Science McMaster University Empirica Therapeutics Medical University of South Carolina Senhwa Biosciences Inc. Breast...
BioCentury | Feb 5, 2019
Distillery Therapeutics

Cancer

...6 μM, respectively). Next steps could include testing the compound in mouse models of RCC. Senhwa Biosciences Inc....
BioCentury | Mar 16, 2018
Finance

Hong Kong’s new chapter

...big hit. TPEx has made a comeback, with seven IPOs in 2016-17 that culminated with Senhwa Biosciences Inc.’s...
...Inc., Zhubei, Taiwan Medigen Biotechnology Corp. (TPEx:3176), Taipei, Taiwan OBI Pharma Inc. (TPEx:4174), Taipei, Taiwan Senhwa Biosciences Inc....
BioCentury | Mar 2, 2018
Clinical News

Senhwa reports Phase I data for CX-5461 in hematologic malignancies

...in December 2017. The trial was conducted in collaboration with the Peter MacCallum Cancer Centre. Senhwa...
...CX-5461 is an oral RNA polymerase I (Pol I) inhibitor and G-quadruplex (G4) DNA stabilizer. Senhwa Biosciences Inc....
...and antitumor activity Status: Phase I data Milestone: Start Phase II (2018) Mary Romeo CX-5461 American Society of Hematology ASH Senhwa Biosciences Inc. RNA...
BioCentury | Dec 22, 2017
Financial News

JHL delisting from TPEx

...next year. JHL Biotech Inc. (TPEx-E:6540), Zhubei, Taiwan Jaime De Leon JHL1101 Genentech Inc. JHL Biotech Inc. Medigen Biotechnology Corp. PharmaEngine Inc. Roche Senhwa Biosciences Inc. TaiGen...
BioCentury | Dec 21, 2017
Financial News

JHL delisting from TPEx

...multiple trials of the candidates next year. Jaime De Leon dornase alfa Herceptin JHL1101 Pulmozyme Rituxan rituximab Genentech Inc. JHL Biotech Inc. Medigen Biotechnology Corp. PharmaEngine Inc. Roche Senhwa Biosciences Inc. TaiGen...
BioCentury | Dec 9, 2017
Product Development

Multimodal meeting

...is developing BNZ-1 to treat large granular lymphocyte leukemia and cutaneous T cell lymphoma (CTCL). Senhwa Biosciences Inc....
...response (PR) at 24 weeks in 14 patients 3256 RNA polymerase I (Pol I) CX-5461 Senhwa Biosciences Inc....
...to treat leukemias Safety, HA-1 specific CD8+ T cell response in 9 healthy volunteers 1908 Senhwa Biosciences Inc....
BioCentury | Aug 17, 2017
Translation in Brief

Stopping the invasion

...in the brain slice model, and in an orthotopic xenograft mouse model (see Distillery ). Senhwa Biosciences Inc....
...a druggable pathway controlling glioblastoma invasiveness." Cell Reports (2017) Winnie Pong, Staff Writer CX-4945 Curtana Pharmaceuticals Inc. Netherlands Cancer Institute Senhwa Biosciences Inc. Casein...
BioCentury | Aug 16, 2017
Distillery Therapeutics

Cancer

...therapies in animal models of GBM (see "Stopping the Invasion." BioCentury Innovations (Aug. 17, 2017)). Senhwa Biosciences Inc....
BioCentury | Jul 7, 2017
Finance

Generalists needed

...NASDAQ:URGN) 5/3/17 $58.2 $155.6 $216.2 39% Zymeworks Inc. (NYSE:ZYME; TSX:ZYME) 4/27/17 $63.6 $319.7 $211.4 -34% Senhwa Biosciences Inc....
Items per page:
1 - 10 of 20